Abstract #1364

Assessment of Anti-EGFRvIII Chimeric Antigen Receptor (CAR) T cell Therapy for Patients with Glioblastomas using Diffusion, Perfusion and MR Spectroscopy

Sumei Wang¹, Donald M O’Rourke², Sanjeev Chawla¹, Gaurav Verma¹, Gabriela Plesa³, Carl H June³, Marcela V Maus⁴, Steven Brem², Eileen Maloney², Jennifer JD Morrissette⁵, Maria Martinez-Lage⁵, Arati Desai⁶, Ronald L Wolf¹, Harish Poptani^1,7, and Suyash Mohan¹

¹Radiology, University of Pennsylvania, Philadelphia, PA, United States, ²Neurosurgery, University of Pennsylvania, Philadelphia, PA, United States, ³Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States, ⁴Center for Cancer Immunology, Massachusetts General Hospital Cancer Center, Charlestown, MA, United States, ⁵Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States, ⁶Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, United States, ⁷Cellular and Molecular Physiology, University of Liverpool, Liverpool, United Kingdom

Chimeric Antigen Receptor (CAR) T cell therapy is a novel method of treating tumors. Since EGFRvIII is expressed in some glioblastomas, we evaluated the efficacy of anti-EGFRvIII CART for treating these tumors. Treatment response was assessed via serial MRI scans at 1 and 2 months after CAR-T cell therapy. The rCBVmax and Cho/Cr ratio decreased whereas MD and FA stayed relatively stable for most patients, indicating a positive response that can be assessed by these methods.

This abstract and the presentation materials are available to members only; a login is required.

Join Here